anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the extraction technology of a rhizoma coptidis total alkaloid and the process flow is as follows: raw materials (rhizoma coptidis or coptis fibrous roots or coptis leaves), pulverization (Coptis fibrous roots or coptis leaves need no pulverizing.), addition of right amount of sulphuric acid of 0.01 to 10 percent for soaking, heated extraction for four times, preconcentration, sediment of sodium chloride and high-valencied metal salt, filtration, drying and products of rhizoma coptidis total alkaloid. The main active ingredients for the product are berberine, coptisine, jateorrhizine, palmatine, epiberberine and other active coptis ingredients, the content of rhizoma coptidis total alkaloid is over 20 percent, wherein, the content of berberine is over 10 percent. The product adopts coptis fibrous roots and so on as raw materials to extract rhizoma coptidis total alkaloid, which is different from the traditional extraction of berberine. The extraction technology improves the pure quotient of the product and particularly eliminates cold-natured ingredients of toxic and side effect through the operating procedure of impurity eliminating, thereby improving the product quality. Besides the traditionally-utilized berberine, the product still contains a large quantity of other active coptis ingredients such as coptisine, jateorrhizine, palmatine, epiberberine and so on. The product has a higher utilization rate of resources and a higher security of products, and the effective function and action of rhizoma coptidis can be brought into a better play.
BACKGROUND/AIMS: Chronic inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are known for a combination of food intolerance, decreased oral intake, and malabsorption which all predispose patients to malnutrition and suboptimal dietary intake. The present study was conducted to 1) examine self-reported food intolerances and dietary supplement use 2) assess nutritional intake 3) assess the nutritional status and screen for malnutrition among patients with chronic inflammatory bowel disease (CIBD).
METHODS: 48 patients with CIBDs (28 Crohn's disease, 15 ulcerative colitis and 7 with atypical forms of IBD) took part in this cross-sectional study. Participants completed a food frequency questionnaire targeting dietary intakes and food trends over time. A questionnaire about food intolerance was also used. The nutritional status of patients with CIBDs was evaluated by a detailed history (medical diagnosis and medications and supplements administered) and by using the subjective global assessment (SGA) tool. Anthropometric data including height, weight, and BMI with body composition assessment using automated scales and stadiometer, while Bio-impedancemetry was used to measure body fat and visceral fat. Statistical analysis was conducted using SPSS 27, employing mean values, standard deviations, absolute and relative frequencies and Pearson's chi-square test, with significance set at p ≤ 0.05.
RESULTS: Food intolerance was equally common in all the types of CIBD specifically for dairy products, spicy foods, and high-fiber food items (beans and raw vegetables). Individuals with CIBD were also complaining about meat and chicken products (68%), followed by alcohol and soda (64%) and fish and sea foods (59%). 17% of the patients were malnourished. A significant percentage of malnourished patients with CIBD had to follow a diet outside the flare, had a nutritional follow up, were currently taking corticosteroids and had a severe form of the disease compared to patients who were well nourished.
CONCLUSIONS: This study has contributed valuable insights into the understanding that some food items could be associated to periods of increased disease activity in CIBD patients and that awareness/intervention regarding nutrition must be provided by healthcare professionals (dietitians, physicians…) to decrease the need for second line therapy. In addition, this self-reported food intolerance paper gives an insight for patients on food items usually avoided by CIBD patients during flares.
OBJECTIVE: This study aims to report the efficacy and safety of double-fenestrated physician-modified endovascular grafts (PMEGs) for total aortic arch repair with at least 3 years of follow-up.
METHODS: All consecutive patients with a pathological aortic arch who underwent aortic arch repair combined with a homemade double-fenestrated stent graft from 2017 to 2020 were reviewed.
RESULTS: 74 patients were treated for pathological arch conditions with a double-fenestrated PMEG. Of these, 81% were male, the mean age was 69.9 years, and 59% were classified as American Society of Anesthesiology 3 or 4. Thirty-five percent were treated for a postdissection aneurysm, 36% for a degenerative aneurysm, and 14% for acute type B dissection. Fifteen percent had supra-aortic trunk dissection. Fenestration on the subclavian artery was performed in 96%; if not, a carotid-subclavian bypass was carried out. Technical success was 100%. The proximal landing zone is consistently in zone 0. Early outcomes revealed a 3% occurrence of type 1 endoleak, which was successfully treated by prompt reintervention. One retrograde dissection occurred, and one patient died from hemorrhage on an iliac conduit. A 5% stroke rate was reported. During long-term follow-up (mean time 40.7 months), one type 1 endoleak appeared and was successfully treated; no type 2 or type 3 endoleak requiring intervention occurred. No stent fractures or migrations were reported. Four percent of patients required reintervention, but no surgical conversion to open surgical repair was needed on the aortic arch. No patient died from a cause related to the main procedure.
CONCLUSIONS: Total aortic arch repair with double-fenestrated PMEGs is associated with acceptable early and midterm major morbidity and mortality. It is suitable for the main aortic pathologies. Moreover, it is easily available for emergency situations.
The histone H3 lysine 9 methyltransferase SETDB1 controls transcriptional repression to direct stem cell fate. Here, we show that Setdb1 expression by adult muscle stem cells (MuSCs) is required for skeletal muscle regeneration. We find that SETDB1 represses the expression of endogenous retroviruses (ERVs) in MuSCs. ERV de-repression in Setdb1-null MuSCs prevents their amplification following exit from quiescence and promotes cell death. Multi-omics profiling shows that chromatin decompaction at ERV loci activates the DNA-sensing cGAS-STING pathway, entailing cytokine expression by Setdb1-null MuSCs. This is followed by aberrant infiltration of inflammatory cells, including pathological macrophages. The ensuing histiocytosis is accompanied by myofiber necrosis, which, in addition to progressive MuSCs depletion, completely abolishes tissue repair. In contrast, loss of Setdb1 in fibro-adipogenic progenitors (FAPs) does not impact immune cells. In conclusion, genome maintenance by SETDB1 in an adult somatic stem cell is necessary for both its regenerative potential and adequate reparative inflammation.
The active ingredient in omeprazole delayed-release capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its molecular formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is:

Omeprazole, USP is a white to off-white crystalline powder that melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.

Each omeprazole delayed-release capsule intended for oral administration contains 10 mg or 20 mg or 40 mg of omeprazole. In addition, each capsule contains the following inactive ingredients: acetone, di-sodium hydrogen phosphate dihydrate, FD&C blue 1, gelatin, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, polyethylene glycol, sodium lauryl sulphate, sugar spheres, talc, titanium dioxide and triethyl citrate. Additionally each 10 mg and 40 mg capsule shell contains FD&C red 3 and FD&C green 3; each 20 mg capsule shell contains iron oxide red and iron oxide yellow. The capsule is printed with black pharmaceutical ink which contains following ingredients: black iron oxide, potassium hydroxide, propylene glycol and shellac.

Omeprazole Delayed-Release Capsules USP meet USP Dissolution Test 2.
The present invention relates to a Chinese medicinal preparation for treating eczematous dermatitis of piglets, which belongs to a veterinary medicine. The Chinese medicinal preparation is prepared from the medicines of the following weight percentage: 35 to 45 of honeysuckle flower, 35 to 45 of isatis root, 5 to 15 of dandelion and 5 to 15 of cyrtomium fortunei. The Chinese medicinal preparation has the advantages of specific medical property of the selected medicines, high pertinence, scientific and reasonable formula composition and simple and clear prescription. The Chinese medicinal preparation has the efficacy of killing bacterium, relieving inflammation, clearing heat and toxic materials, activating blood circulation to dissipate blood stasis and converging and eliminating dampness. In clinical application, the Chinese medicinal preparation can be directly fed to piglets. For sucking piglets, the Chinese medicinal preparation can be directly fed to a sow, and the treatment effect on the piglets can be achieved indirectly. Compared with antibiotic drugs, the cure rate of the Chinese medicinal preparation is increased by 33.6%, and the course of treatment is shortened by 46.18%.
The invention relates to a ginseng rhizoma gastrodiae elatae pill which has the effects of tonifying kidney, invigorating qi, tonifying spleen and invigorating blood circulation. It is necessary to tonify the kidney, because the kidney is the basis of a human body; it is necessary to tonify the spleen, because the spleen is a germinal organ; it is necessary to invigorate qi, because qi refers to the most basic energy for constituting the human body and for maintaining life activities, at the same time, qi has a meaning of physiological function; evil cannot invade if healthy qi is enough; besides, the pill can invigorate the blood circulation. A specific formulation of the pill comprises 15 g of the gingeng (or red ginseng, radix scrophulariae), 15 g of bighead atractylodes rhizome, 15 g of morinda officinalis, 15 g of rhizoma gastrodiae elatae and 15 g of jujubae. The above materials are decocted with water for oral dose or made into large particle pills, or made into decocted liquid concentrated pills. One dose is taken every day. The large particle pills are in the same amount of the raw materials. The taking amount can be adjusted according to disease degrees of patients. For a patient with a mild symptom, the taking amount can be less; and for a patient with a server symptom, the taking amount can be more. The formula needs to be taken for a long time. The patient with the mild symptom can be healed by taking the pills for one to two years; and the patient with the server symptom can be healed by taking the pills for three to five years. The pill has the beneficial effect that the patient with the mild symptom can be healed and the symptom of the patient with the server symptom can be alleviated by taking the pill for a long time.
Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
The present invention provides a method for preparing granules which contain ibuprofen arginine compositions. The composition is prepared from ibuprofen arginine used as main medicament, a diluting agent and an adhesive agent. The method comprises a granulating step and a coating step. A coating solution is prepared from coating material which contains silicon dioxide; prepared granules are coated with the coating solution. The granules prepared by the method are coated, the defect that the ibuprofen arginine easily absorbs water is overcome, and the penetrating odor of medicine is covered. According to the method, tabletting granules of tablets and granules as content of capsules can be prepared. A conventional solid preparation prepared by the method has the advantages of high stability, rapid disintegration and high biological availability.
<P>PROBLEM TO BE SOLVED: To provide a method for purifying a recombinant protein selected from the group consisting of E1 and/or E2 and/or E1/E2.  <P>SOLUTION: The present invention relates to the method for purifying the recombinant protein selected from the group consisting of E1 and/or E2 and/or E1/E2. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
When the retractor blades oped and is positioned to provide the surgical access in the anterior cervical spine surgery, it cause the trachea to deviate laterally and pose pressure on the tissue between the retractor and the trachea. The most important structure is the recurrent laryngeal nerve. This is convincible as revealed by the increase of cuff pressure of endotracheal tube. The pressure created by the retractor may be related to postoperative dysphonia and dysphagia. In view of minimizing the pressure created by the retractors, some neurosurgeons advocate to deflate then to inflate the cuff of ETT tube after the retractor is on, while some advocate monitoring of cuff pressure and keep below 25 mmHg. Nasotracheal or orotracheal tube can both be applied to general anesthesia for the anterior cervical spine surgery. The option depends on the surgeons' preference. Though both approaches end at the trachea, the nasotracheal tube is fixed at the nostril, and orotracheal tube, at the mouth angle, on the opposite side of surgical approach. The investigators hypothetize this difference in location results in different degree of deviation and increase of cuff pressure. The study aims to investigate differences in the increase of cuff pressure after retractor is positioned between nasoendotracheal and oroendotracheal intubation.

Apfelbaum and colleagues indicated the asymmetric position of the oroETT within the larynx as being fixed distally by the cuff and proximally by taping at the mouth angle. The asymmetry of the tube shaft and cuff may contribute to unilateral vocal palsy. When the retractors are set up for ACCS, the deviation of cuff towards the retractors increases ETCP and creates a extrusion compression of tissues in between the cuff and the retractor blade. Nasotracheal intubation follows a more natural trajectory into the trachea. In theory, a nasoETT is more centrally located and less asymmetric in the thyroid cartilage and trachea; thus pressure from this tube may be relatively evenly distributed, and the pressure on the surrounding tissues is lower. Therefore, we hypothesised lower degree of tissue compression with a nasoETT, even during retractor splay. The effect may be reflected in intraoperative ETCP or post-ACCS dysphonia. This randomised controlled clinical trial assessed the differences in the tracheal intubation mode on the maximal ETCP during retractor splay (primary endpoint) and post-ACSS dysphonia (secondary endpoint).
The sterile device and gamma rays, latex free and disposable consists of the following components: a steel canister, a catheter 2m hose, one attack base located at the proximal end of the catheter, one unit at the end back, two needles and two syringes. The device must always be stored in the original packaging. Store only in one place Temp temperature not exceeding 30°C(86°)Application procedure: The device must be pr repaired and activated adequately in order to ensure its correctness operation. See instructions for assembly and indoor use of the package.
OBJECTIVE: Greater trochanteric pain syndrome (GTPS) is a prevalent condition that can significantly affect patient comfort and function. This study aims to compare the effectiveness of ultrasound (USG)-guided and anatomic landmark-guided corticosteroid injections in managing GTPS.
METHODS: Patients diagnosed with GTPS received either USG or anatomic landmark-guided corticosteroid injections. Pain scores (Visual Analog Scale, VAS) and functional outcomes (modified Harris Hip Score, HHS) were assessed at baseline, 1 month, and 1 year postinjection. Cost-effectiveness was calculated using public and private payor pricing from June 2024.
RESULTS: Both treatment groups exhibited significant improvements in pain and function. The USG group demonstrated greater initial improvements at the 1-month mark, particularly in VAS activity and HHS. However, these differences between the groups converged over time, with similar long-term outcomes observed in these parameters. The USG-guided injections showed more pronounced initial benefits, especially for patients with higher initial pain levels and lower functional scores. USG was found to be more cost-effective in terms of HHS, but not VAS measures.
CONCLUSION: While both USG and anatomic landmark-guided injections are effective for managing GTPS, USG-guided injections may provide greater initial relief in pain and function, particularly for patients with higher initial pain levels. USG does not demonstrate longterm superiority over anatomic injections. The study underscores the importance of evaluating long-term outcomes to comprehensively assess the sustained effectiveness of different treatment strategies for GTPS.
LEVEL OF EVIDENCE: Level III, Therapeutic study.
BACKGROUND & AIMS: The differences in the association of body mass index (BMI) with mortality between older adults with and without frailty remain unclear. This study investigated this association in community-dwelling older adults with and without frailty.
METHODS: This prospective study included 10,912 adults aged ≥65 years who provided valid responses to a baseline mail survey questionnaire in the Kyoto-Kameoka Study in Japan. The BMI was calculated based on self-reported height and body weight and classified into four categories: <18.5, 18.5-21.4, 21.5-24.9, and ≥25.0 kg/m2. Frailty was evaluated using the validated Kihon Checklist and defined as a score of 7 or higher out of a possible 25 points. Mortality data were collected from 30 July 2011 to 30 November 2016. Hazard ratios (HR) for all-cause mortality were calculated using a multivariable Cox proportional hazards model.
RESULTS: During the 5.3 year median follow-up period (54,084 person-years), 1352 deaths were recorded. After adjusting for confounders, including lifestyle and medical history, compared with participants with a BMI of 21.5-24.9 kg/m2, those in the lower BMI category had a higher mortality HR, while those with a higher BMI displayed an inverse association with mortality (<18.5 kg/m2: HR: 1.85, 95% confidence interval [CI]: 1.58-2.17; 18.5-21.4 kg/m2: HR: 1.38, 95% CI: 1.21-1.58; and ≥25.0 kg/m2: HR: 0.80, 95% CI: 0.67-0.96). In a model stratified by frailty status, the BMI range with the lowest HR for mortality was 23.0-24.0 kg/m2 in non-frail older adults; however, in frail older adults, a higher BMI was inversely associated with mortality.
CONCLUSIONS: The relationship between BMI and mortality varies between individuals with and without frailty, with those experiencing frailty potentially benefiting from a higher BMI compared to those without frailty. This study suggests that frailty should be assessed when considering the optimal BMI for the lowest mortality risk among older adults.
Infection by bacteria leads to tissue damage and inflammation, which need to be tightly controlled by host mechanisms to avoid deleterious consequences. It is previously reported that TMEM16F, a calcium-activated lipid scramblase expressed in various immune cell types including T cells and neutrophils, is critical for the control of infection by bacterium Listeria monocytogenes (Lm) in vivo. This function correlated with the capacity of TMEM16F to repair the plasma membrane (PM) damage induced in T cells in vitro, by the Lm toxin listeriolysin O (LLO). However, whether the protective effect of TMEM16F on Lm infection in vivo is mediated by an impact in T cells, or in other cell types, is not determined. Herein, the immune cell types and mechanisms implicated in the protective effect of TMEM16F against Lm in vivo are elucidated. Cellular protective effects of TMEM16F correlated with its capacity of lipid scrambling and augment PM fluidity. Using cell type-specific TMEM16F-deficient mice, the indication is obtained that TMEM16F expressed in liver Kupffer cells (KCs), but not in T cells or B cells, is key for protection against Listeria in vivo. In the absence of TMEM16F, Listeria induced PM rupture and fragmentation of KCs in vivo. KC death associated with greater liver damage, inflammatory changes, and dysregulated liver metabolism. Overall, the results uncovered that TMEM16F expressed in Kupffer cells is crucial to protect the host against Listeria infection. This influence is associated with the capacity of Kupffer cell-expressed TMEM16F to prevent excessive inflammation and abnormal liver metabolism.
The invention relates to a method for the modification, in particular the polymerisation, of haemoglobin in which the reaction is carried out in vitro with intact erythrocytes. It is possible in this way by using the agents known per se to alter the oxygen affinity. The modification, in particular the polymerisation, of haemoglobin can be carried out by the action of polyfunctional agents, preferably in isotonic solution. It is possible to use as polymerising agent, for example, glutaraldehyde. Animal erythrocytes, in particular bovine erythrocytes, can be used as starting material. It is possible to break down blood-group-active molecular structures on the erythrocyte surface by means of enzymes, for example neuraminidase. The method according to the invention results, for example, in polymers with a molecular weight of 60000 to more than 6x10<6> dalton which have high oxygen transport capacity and low methaemoglobin content.
A composition comprising oil palm phenolics and shikimic acid or derivatives and use thereof. The oil palm phenolics are selected from protocatechuic acid, p-hydroxybenzoic acid, 4-caffeoylshikimic acid, 3-eaffecylshikimic acid, 5-caffeoylshikimic acid or mixtures thereof. The shikimic acid derivatives include 3-dehydroshikimic acid. The composition comprises bioactive compounds selected from peptides, minerals, oligosaccharides and mixtures thereof. The composition further comprises pharmaceutically acceptable carriers. The composition is applied topically, as a skin dermal patch, as a skin spray or as a nasal or intravenous solution. The composition can be used for ameliorating oxidative stress or inflammation, as well as to inhibit nitrite in biological systems. Also disclosed is use of shikimic acid or derivatives to enhance anti-oxidative properties of anti-oxidative agents, as well as to enhance anti-inflammatory properties of anti-inflammatory agents.